PapersFlow Research Brief
Magnolia and Illicium research
Research Guide
What is Magnolia and Illicium research?
Magnolia and Illicium research is the study of therapeutic compounds honokiol and magnolol from the Magnolia family, and related extracts from Illicium verum, focusing on their anticancer, neuroprotective, anti-inflammatory, and antioxidative properties including apoptosis induction and angiogenesis inhibition.
This field encompasses 10,347 published works examining honokiol and magnolol derived from Magnolia species for applications in inducing apoptosis, inhibiting angiogenesis, and serving as chemotherapy candidates. Key studies demonstrate honokiol's role in blocking cardiac hypertrophy via mitochondrial Sirt3 activation and inhibiting tumor growth in vivo. Research also covers Illicium verum's botany, traditional uses, chemistry, and pharmacology.
Topic Hierarchy
Research Sub-Topics
Honokiol Anticancer Mechanisms
This sub-topic investigates honokiol's induction of apoptosis and inhibition of proliferation in cancer cells via mitochondrial and PI3K/Akt pathways. Researchers evaluate synergy with chemotherapeutics.
Magnolol Anti-inflammatory Properties
This sub-topic explores magnolol's suppression of NF-κB and cytokine production in inflammatory models. Studies span arthritis, colitis, and neuroinflammation.
Honokiol Neuroprotective Effects
This sub-topic examines honokiol's protection against ischemia, Alzheimer's, and Parkinson's via antioxidant and anti-amyloid mechanisms. Preclinical models assess blood-brain barrier penetration.
Magnolia Compounds Angiogenesis Inhibition
This sub-topic studies honokiol and magnolol's blockade of VEGF signaling and tube formation in endothelial cells. Research translates to tumor xenograft models.
Safety and Toxicology of Honokiol Magnolol
This sub-topic evaluates pharmacokinetics, toxicity profiles, and drug interactions of honokiol and magnolol in preclinical and clinical studies. Dose-escalation data guide safe dosing.
Why It Matters
Compounds from Magnolia, such as honokiol and magnolol, show potential in treating cardiac hypertrophy, as honokiol blocks and reverses it in mice by activating mitochondrial Sirt3, according to Pillai et al. (2015) in "Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3" (427 citations). These natural products inhibit angiogenesis and tumor growth, with honokiol reducing tumor angiogenesis in vivo as reported by Bai et al. (2003) in "Honokiol, a Small Molecular Weight Natural Product, Inhibits Angiogenesis in Vitro and Tumor Growth in Vivo" (340 citations). Fried and Arbiser (2009) in "Honokiol, a Multifunctional Antiangiogenic and Antitumor Agent" (314 citations) highlight honokiol's antiangiogenic and antitumor effects. Safety profiles are established in Sarrica et al. (2018) "Safety and Toxicology of Magnolol and Honokiol" (243 citations), supporting clinical translation. Illicium verum extracts are reviewed for pharmacology by Wang et al. (2011) in "Illicium verum: A review on its botany, traditional use, chemistry and pharmacology" (275 citations), with broader therapeutic uses outlined by Lee et al. (2011) in "Therapeutic applications of compounds in the Magnolia family" (467 citations).
Reading Guide
Where to Start
"Therapeutic applications of compounds in the Magnolia family" by Lee et al. (2011), as it provides a broad overview of honokiol and magnolol's pharmacological uses across diseases, serving as an accessible entry to the field's scope (467 citations).
Key Papers Explained
Lee et al. (2011) "Therapeutic applications of compounds in the Magnolia family" establishes the foundational pharmacology of Magnolia compounds. Bai et al. (2003) "Honokiol, a Small Molecular Weight Natural Product, Inhibits Angiogenesis in Vitro and Tumor Growth in Vivo" builds on this by demonstrating honokiol's antiangiogenic mechanisms using Magnolia grandiflora extracts. Fried and Arbiser (2009) "Honokiol, a Multifunctional Antiangiogenic and Antitumor Agent" extends these findings to antitumor properties. Pillai et al. (2015) "Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3" applies honokiol to cardiac applications, linking back to its anti-inflammatory base.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research centers on mechanistic depth in cardiac protection and oncology, as in Pillai et al. (2015) on Sirt3 pathways and safety validation via Sarrica et al. (2018). No recent preprints or news indicate steady progress without major shifts.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Quelques propriétés globales des variétés différentiables | 1954 | Commentarii Mathematic... | 810 | ✕ |
| 2 | Natural product agonists of peroxisome proliferator-activated ... | 2014 | Biochemical Pharmacology | 573 | ✓ |
| 3 | Therapeutic applications of compounds in the Magnolia family | 2011 | Pharmacology & Therape... | 467 | ✕ |
| 4 | Honokiol blocks and reverses cardiac hypertrophy in mice by ac... | 2015 | Nature Communications | 427 | ✓ |
| 5 | Honokiol, a Small Molecular Weight Natural Product, Inhibits A... | 2003 | Journal of Biological ... | 340 | ✓ |
| 6 | Honokiol, a Multifunctional Antiangiogenic and Antitumor Agent | 2009 | Antioxidants and Redox... | 314 | ✓ |
| 7 | Factorization in integral domains | 1990 | Journal of Pure and Ap... | 298 | ✕ |
| 8 | Illicium verum: A review on its botany, traditional use, chemi... | 2011 | Journal of Ethnopharma... | 275 | ✕ |
| 9 | On 2-absorbing ideals of commutative rings | 2007 | Bulletin of the Austra... | 252 | ✓ |
| 10 | Safety and Toxicology of Magnolol and Honokiol | 2018 | Planta Medica | 243 | ✓ |
Frequently Asked Questions
What are the primary therapeutic properties of honokiol from Magnolia?
Honokiol exhibits anti-inflammatory, anti-oxidative, anti-tumour, and neuroprotective properties. Pillai et al. (2015) showed it blocks agonist-induced and pressure overload-mediated cardiac hypertrophic responses in mice by activating mitochondrial Sirt3. Bai et al. (2003) demonstrated it inhibits angiogenesis in vitro and tumor growth in vivo.
How does magnolol contribute to Magnolia research?
Magnolol, alongside honokiol, is a neolignan from Magnolia officinalis and Magnolia obovata bark used in traditional medicines for sedative, antioxidant, anti-inflammatory, antibiotic, and antispastic effects. Sarrica et al. (2018) reviewed its safety and toxicology, confirming low toxicity profiles. Lee et al. (2011) outlined its broad therapeutic applications.
What role does Illicium verum play in this research?
Illicium verum is examined for its botany, traditional use, chemistry, and pharmacology. Wang et al. (2011) provided a comprehensive review in "Illicium verum: A review on its botany, traditional use, chemistry and pharmacology" (275 citations). It connects to natural product research alongside Magnolia compounds.
What are the anticancer mechanisms of Magnolia compounds?
Honokiol induces apoptosis and inhibits angiogenesis. Fried and Arbiser (2009) described it as a multifunctional antiangiogenic and antitumor agent in "Honokiol, a Multifunctional Antiangiogenic and Antitumor Agent" (314 citations). Bai et al. (2003) showed it inhibits tumor growth in vivo using Magnolia grandiflora extracts.
What is known about the safety of honokiol and magnolol?
Magnolol and honokiol from Magnolia bark have been used for thousands of years with established safety. Sarrica et al. (2018) detailed their toxicology in "Safety and Toxicology of Magnolol and Honokiol", noting low toxicity and supporting herbal preparation use. No major adverse effects were highlighted in preclinical studies.
Open Research Questions
- ? How can honokiol's Sirt3 activation pathway be optimized for human cardiac hypertrophy treatment?
- ? What specific molecular targets does honokiol use to inhibit angiogenesis beyond endothelial cells?
- ? Can combinations of honokiol, magnolol, and Illicium verum compounds enhance anticancer efficacy?
- ? What are the long-term toxicological thresholds for chronic Magnolia compound administration?
- ? How do genetic variations affect responses to Magnolia-derived neuroprotective agents?
Recent Trends
The field maintains 10,347 works with no specified 5-year growth rate.
Citation leaders include Lee et al. at 467 for therapeutic applications, Pillai et al. (2015) at 427 for cardiac effects, and Sarrica et al. (2018) at 243 for toxicology, reflecting sustained interest in clinical viability.
2011No recent preprints or news coverage in the last 12 months or 6 months.
Research Magnolia and Illicium research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Magnolia and Illicium research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers